by Rhoda Wilson, Expose News:
The Serum Institute of India, already the largest vaccine manufacturer in the world, is set to launch a new malaria vaccine by June and play a crucial role in responding to future outbreaks within 100 days. Before the covid pandemic, the institute’s vaccines reached nearly two-thirds of the world’s children. With the malaria vaccine, Serum wants to make itself indispensable, globally.
Producing covid injections, including the Oxford/AstraZeneca vaccine, propelled Serum to the forefront of supplying vaccines to the COVAX facility for low and middle-income countries.
TRUTH LIVES on at https://sgtreport.tv/
The institute aims to consolidate its reputation as the vaccine manufacturer for the world’s poorest. It is about to distribute 25 million doses of its malaria vaccine, developed with the University of Oxford, in sub-Saharan Africa.
Serum has also partnered with the Coalition for Epidemic Preparedness Innovations (“CEPI”) to provide emergency vaccines during future pandemics. The company is working to improve pandemic preparedness and has committed to maintaining production facilities on standby through its partnership with CEPI.
It is also working on a pipeline of vaccines, including an HPV immunisation and a dengue vaccine, and is exploring the prevention of tuberculosis.
Bill Gates’ GAVI wants vaccines to be manufactured locally in Africa, in facilities developed using GAVI’s new US$1 billion financing instrument called the African Vaccine Manufacturing Accelerator launched in December 2023. However, India’s Serum Institute is pushing back.
Bill Gates’ GAVI, COVAX and CEPI
GAVI, originally known as Global Alliance for Vaccines and Immunisation, is a public–private partnership created in 2000. The seed money to launch GAVI was provided by Bill Gates. During the period 2021-2025, the Bill & Melinda Gates Foundation is the fourth highest donor to GAVI, after the USA, the UK and Germany. Its core partners are listed as its core partners, the World Health Organisation, UNICEF, the World Bank and the Bill & Melinda Gates Foundation.
GAVI launched the Covid-19 Vaccines Global Access (“COVAX”) facility in June 2020. By 19 October 2020, 184 countries had joined COVAX. From 2020 to 2023, it was co-led by GAVI the Vaccine Alliance, CEPI, the World Health Organisation (WHO) and UNICEF. WHO describes it as: “COVAX was a historic multilateral effort” that came to a close on 31 December 2023.
CEPI is a global public-private partnership that was launched after the response to the 2014-2016 West Africa Ebola epidemic. The idea was seeded in a 2015 paper published in The New England Journal of Medicine, which was co-authored by Wellcome Trust Director Jeremy Farrar.
It was founded by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome and the World Economic Forum (“WEF”) and launched at WEF’s annual meeting in Davos, Switzerland, in 2017 with an initial investment from the governments of Germany, Japan and Norway, plus the Bill & Melinda Gates Foundation and the Wellcome Trust.
A press release announcing its launch stated: “CEPI is also backed by major pharmaceutical corporations, the World Health Organisation and Médecins Sans Frontières / Doctors Without Borders, as well as philanthropies and leading academic vaccine research groups.”
Notably, CEPI refers to its supporters as “investors” and not “funders” or “donors.” As of December 2023, the Bill & Melinda Gates Foundation and Wellcome Trust are the two largest private investors. These investments together represent the fourth largest investors, after Germany, Norway and the UK.
There is an obvious common private and influential “donor” or investor in all three of GAVI, COVAX and CEPI: Bill & Melinda Gates.
Further reading:
- How Bill Gates and partners’ money controlled the World’s draconian covid plan
- WHO, Bill Gates and Wellcome Trust’s Global Vaccine Fund lacks transparency and accountability
- Wellcome Leap teams up with CEPI For RNA Readiness and Response Part 1 and Part 2
- Bill Gates peddles ineffective malaria vaccines to poorer nations
- Serum Institute on The Exposé
GAVI, WHO and related organisations are funding local vaccine development in an attempt to fool people in developing nations that the vaccines to be forced on them are their own
“GAVI plans to spend a billion dollars on local vaccine production, see HERE. But some say local production is a bad idea. I do too, because it is simply a scam; you cannot set up a vaccine factory without a massive infrastructure to support it and well-trained and well-honed staff to manage it and troubleshoot the problems as they arise.” Dr. Meryl Nass wrote in a Substack article.
Dr. Nass added, “India’s Serum Institute is the world’s largest vaccine manufacturing facility and they are pushing back, although for commercial reasons, explaining that local production will actually cost more.”
Dr. Nass was referring to an article highlighted in a Newswire dated 29 March 2024 by Devex senior editor Helen Murphy. “One lesson the Serum Institute’s leadership has drawn from the Indian company’s history is a commitment to economies of scale – and that’s led them to resist the growing demand for local vaccine production,” she wrote.
Devex reports “from the front lines of the fight to achieve the SDGs.” The SDGs are the UN Agenda 2030’s 17 Sustainable Development Goals.
The outlet boasts: “Among our readers, we count leaders so prominent one name is sufficient, from Tedros to Kristalina to Melinda. We give members of Parliament, Congress, development agencies, philanthropists, researchers, multilateral banks, and NGOs the news they need to do their job.”
Taking their own words at face value, Devex is a media outlet for Globalists and exemplifies the Global Public Private Partnership.
(Related: The Carlyle Group: An example of how the Global Public Private Partnership works)
Commenting on Devex’s article ‘Local doesn’t mean low cost: Serum Institute shares global scale-up plans’ Dr. Nass said (emphasis is hers):
Anyone in the vaccine game knows of the Serum Institute. Already the world’s largest vaccine manufacturer – and a critical conduit of jabs to lower-income countries – the Indian biotechnology company is looking to make itself globally indispensable with a new malaria vaccine and a critical role in a new venture to respond to future outbreaks in less than 100 days.
But while Serum is expanding rapidly, it doesn’t believe local communities should be trying to follow in its footsteps.
One of the lessons that Serum’s CEO Adar Poonawalla has drawn from his company’s history is a commitment to economies of scale – and that has led him to caution against the burgeoning demand for local production, which grew out of the blatant vaccine hoarding seen during the covid-19 pandemic.
